Revolution Medicines, Inc.
RVMDNext catalyst
RMC-6236
Colorectal Cancer
Get an email about RVMD's next catalysts
Track Revolution Medicines (RVMD) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 2 more upcoming events in our data (earnings, Phase 2 readout).See the timeline
3 upcoming, 1 past
RVMD Earnings Report
EPS Est: $-2.34 | FQ end Sep/2026 | Call: amc
RMC-6236 Phase 2 Est. Readout
Primary completion for RMC-6236 trial (NCT05379985) in Non-small Cell Lung Cancer (NSCLC)
SourceRMC-6236 Phase 2 Est. Readout
Primary completion for RMC-6236 trial (NCT06162221) in Non-Small Cell Lung Cancer, NSCLC
SourceHow RVMD's past catalysts played out
Market Overview
Stock performance and key metrics
RMC-6236
Colorectal Cancer
Leucovorin (Calcium Folinate)
Pancreatic Cancer
zoldonrasib
Pancreatic Cancer
Gemcitabine (GEM)
Pancreatic Cancer
pemetrexed + cisplatin/carboplatin
NSCLC
Liposomal irinotecan
Pancreatic Cancer
daraxonrasib
NSCLC (Non-small Cell Lung Cancer)
cetuximab (Cohort C2 Only)
Advanced Solid Tumors
Daraxonrasib (Cohort B1 only)
Advanced Solid Tumors
TNG462
PDAC
Carboplatin/Cisplatin + Pemetrexed (Cohort B2 Only)
Advanced Solid Tumors
mFOLFIRINOX regimen
Colorectal Cancer
RMC-9805
Colorectal Cancer
Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only)
Advanced Solid Tumors
RMC-4630
Non-Small Cell Lung Cancer
RMC-6291
Non-Small Cell Lung Cancer, NSCLC
Cobimetinib
Solid Tumor
mFOLFOX6 regimen
Colorectal Cancer
Ivonescimab
Advanced Solid Tumors
Elironrasib
Advanced Solid Tumors
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
RMC-6236 | Phase 3 | Colorectal Cancer | - | - |
Leucovorin (Calcium Folinate) | Phase 3 | Pancreatic Cancer | - | - |
zoldonrasib | Phase 3 | Pancreatic Cancer | - | - |
Gemcitabine (GEM) | Phase 3 | Pancreatic Cancer | - | - |
pemetrexed + cisplatin/carboplatin | Phase 3 | NSCLC | - | - |
Liposomal irinotecan | Phase 3 | Pancreatic Cancer | - | - |
daraxonrasib | Phase 3 | NSCLC (Non-small Cell Lung Cancer) | - | - |
cetuximab (Cohort C2 Only) | Phase 2 | Advanced Solid Tumors | - | - |
Daraxonrasib (Cohort B1 only) | Phase 2 | Advanced Solid Tumors | - | - |
TNG462 | Phase 2 | PDAC | - | - |
Carboplatin/Cisplatin + Pemetrexed (Cohort B2 Only) | Phase 2 | Advanced Solid Tumors | - | - |
mFOLFIRINOX regimen | Phase 2 | Colorectal Cancer | - | - |
RMC-9805 | Phase 2 | Colorectal Cancer | - | - |
Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only) | Phase 2 | Advanced Solid Tumors | - | - |
RMC-4630 | Phase 2 | Non-Small Cell Lung Cancer | - | - |
RMC-6291 | Phase 2 | Non-Small Cell Lung Cancer, NSCLC | - | - |
Cobimetinib | Phase 2 | Solid Tumor | - | - |
mFOLFOX6 regimen | Phase 2 | Colorectal Cancer | - | - |
Ivonescimab | Phase 2 | Advanced Solid Tumors | - | - |
Elironrasib | Phase 2 | Advanced Solid Tumors | - | - |
Colorectal Cancer
1 drug in this indication
Non-Small Cell Lung Cancer, NSCLC
1 drug in this indication
Solid Tumor
1 drug in this indication
NSCLC (Non-small Cell Lung Cancer)
1 drug in this indication
Non-Small Cell Lung Cancer
1 drug in this indication
non-small cell lung cancer (RAS mutant)
1 drug in this indication
metastatic pancreatic cancer
1 drug in this indication
advanced pancreatic cancer
1 drug in this indication
pancreatic cancer
1 drug in this indication
pancreatic ductal adenocarcinoma
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Revolution Medicines, Inc.'s drug pipeline?→
CatalystAlert tracks 20 drug candidates in Revolution Medicines, Inc.'s (RVMD) pipeline across Phase 3, Phase 2. Its lead program is RMC-6236 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Revolution Medicines, Inc.'s next FDA catalyst?→
Revolution Medicines, Inc.'s (RVMD) next tracked catalyst is a Phase 2 readout expected Q2 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track RVMD biotech catalysts?→
Add RVMD to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Revolution Medicines, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.